G01N 33/5759
Involving compounds localised on the membrane of tumour or cancer cells
Official title: {involving compounds localised on the membrane of tumour or cancer cells}
G01N33/5759 (Involving compounds localised on the membrane of tumour or cancer cells) appears on 1,938 US grants and 3,994 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,938
- Published applications
- 3,994
- Assignees
- 1,418
- Inventors
- 6,145
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 12 | 0 |
| 1998 | 10 | 0 |
| 1999 | 17 | 0 |
| 2000 | 11 | 0 |
| 2001 | 12 | 1 |
| 2002 | 11 | 22 |
| 2003 | 10 | 512 |
| 2004 | 4 | 53 |
| 2005 | 13 | 62 |
| 2006 | 16 | 78 |
| 2007 | 52 | 79 |
| 2008 | 75 | 58 |
| 2009 | 20 | 91 |
| 2010 | 55 | 93 |
| 2011 | 39 | 73 |
| 2012 | 48 | 88 |
| 2013 | 59 | 114 |
| 2014 | 66 | 218 |
| 2015 | 91 | 217 |
| 2016 | 113 | 204 |
| 2017 | 121 | 231 |
| 2018 | 136 | 228 |
| 2019 | 148 | 203 |
| 2020 | 148 | 216 |
| 2021 | 124 | 242 |
| 2022 | 127 | 227 |
| 2023 | 103 | 187 |
| 2024 | 107 | 187 |
| 2025 | 107 | 166 |
| 2026 | 64 | 144 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Means and methods for the diagnosis, classification and/or monitoring of pediatric tumors6 Oct 2026US 12,754,186 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Composition for cancer cell adhesion, cancer cell collection filter, and method for detecting cancer cell15 Sep 2026US 12,736,538 B2Kyushu University, National University Corporation
- CD8 binding agents and uses thereof25 Aug 2026US 12,715,920 B2Genentech, Inc.
- Anti-human neurotensin receptor 1 antibody and use thereof18 Aug 2026US 12,710,427 B2National Health Research Institutes
- Method for predicting the response to CDK4/6 inhibitor therapy in cancer patients11 Aug 2026US 12,703,885 B2Gbg Forschungs GmbH
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Combination therapy of polio virus receptor inhibitors and fucose8 Oct 2026US 2026/0309713 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Immunohistochemistry (ihc) protocols and methods for diagnosing and treating cancer - claudin 18.28 Oct 2026US 2026/0309714 A1Agilent Technologies, Inc.
- Novel lilrb2 antibodies and uses thereof8 Oct 2026US 2026/0309715 A1Board of Regents, The University of Texas System
- Neu5gc-lewis a-targeting molecules and uses thereof in cancer1 Oct 2026US 2026/0295060 A1SRI International
Most cited
By later US patents
- Methods and reagents for the rapid and efficient isolation of circulating cancer cells288US 6,365,362 B1Board of Regents, The University of Texas System · 2002
- Methods and reagents for the rapid and efficient isolation of circulating cancer cells213US 6,645,731 B2Immunivest Corporation · 2003
- Production of chimeric mouse-human antibodies with specificity to human tumor antigens195US 5,576,184 AXoma Corporation · 1996
- Tissue analysis and kits therefor193US 6,573,043 B1Genentech, Inc. · 2003
- Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell179US 6,132,992 ABristol-Myers Squibb Company · 2000